For breast cancer patients, the era of personalized medicine may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School.
In a July 11 study in Science, Yu and her colleagues report how they isolated breast cancer cells circulating through the blood streams of six patients. Some of these deadly cancer cells are the “seeds” of metastasis, which travel to and establish secondary tumors in vital organs such as the bone, lungs, liver and brain.
Yu and her colleagues managed to expand this small number of cancer cells in the laboratory over a period of more than six months, enabling the identification of new mutations and the evaluation of drug susceptibility.
If perfected, this technique could eventually allow doctors to do the same: use cancer cells isolated from patients’ blood to monitor the progression of their diseases, pre-test drugs and personalize treatment plans accordingly.
Read more . . .
The Latest on: Breast cancer personalized treatment
[google_news title=”” keyword=”Breast cancer personalized treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Breast cancer personalized treatment
- Cancer Testing Product Market Rising to Greatness Anticipating Market Size’s New Heightson April 30, 2024 at 5:59 pm
The Cancer Testing Product market has exhibited notable growth dynamics. Commencing at $$ Million USD in 2016, it escalated to $$ Million USD in 2020, and is projected to achieve $$ Million USD by ...
- Susan G. Komen® Urges Personalized Approach in Response to Breast Cancer Screening Recommendationson April 30, 2024 at 8:30 am
Susan G. Komen®, the world’s leading breast cancer organization, today commented on the final recommendations made by the U.S. Preventive Services Task Force (USPSTF), advocating biennial screening ...
- From Stigma To Support: Empowering Progress Despite Barriers In Breast Canceron April 30, 2024 at 4:00 am
Komen, one of the world's leading breast cancer organizations. Many years ago, there was—and still is, to an extent—a pervasive stigma around breast cancer. But in the 17 years since my own breast ...
- Ricoh and SimBioSys Partner on AI-Powered 3D Models for Personalized Breast Cancer Treatmenton April 26, 2024 at 6:59 am
By joining forces, these two companies are committed to pushing back the boundaries of medical innovation by combining SimBioSys’ cutting-edge artificial intelligence with Ricoh’s 3D printing know-how ...
- Breast Cancer Market To Reach USD 4.3 Billion By 2032, Says DataHorizzon Researchon April 23, 2024 at 2:41 am
The breast cancer market size was valued at USD 2.1 Billion in 2023 and is expected to reach a market size of USD 4.3 Billion by 2032 at a CAGR of 8.1%.Fort Collins, Colorado, April 23, 2024 (GLOBE ...
- Lab, pharma company partner to push biomarker testing to determine cancer treatment approachon April 17, 2024 at 9:05 am
Breast cancer is currently the world’s mostly commonly diagnosed cancer. It is a form of cancer that originates from breast tissue. When diagnosed and treated early, breast cancer is often curable. In ...
- ‘Here’s How I Knew I Had Breast Cancer’: One Survivor’s Story Following a Slightly Delayed Mammogramon April 17, 2024 at 3:01 am
Sometimes breast cancer can emerge between routine mammograms. Five years after recovery, one patient's story reinforces the importance of scheduling that screening.
- The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patientson April 16, 2024 at 6:15 pm
Breast cancer is now the world's most common cancer; at the end of 2020, 7.8 million women were alive having been diagnosed in the previous five years.
- Many people with breast cancer 'systematically left behind' due to inaction on inequities and hidden sufferingon April 15, 2024 at 3:30 pm
Breast cancer is now the world's most common cancer; at the end of 2020, 7.8 million women were alive after having been diagnosed in the previous five years. In the same year, 685,000 women died from ...
- Promising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatmenton April 15, 2024 at 9:05 am
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) today and set a price target ...
via Bing News
